Peutz-Jeghers syndrome (SPEG) is a rare hereditary disorder characterized by tissue dysplasia of the above type, and a predisposition to the formation of various tumor types: hyperplastic polyps, adenomas and carcinomas in various organs, especially in the gastrointestinal tract. The clinical manifestation of the syndrome includes pigmentation of the skin, mucous membranes and the presence of polyps in the gastrointestinal tract. This condition is associated with mutations in genes responsible for cell proliferation and differentiation, mechanisms that control cell growth. The first part of this text will introduce the reader to the hereditary nature of the syndrome, its inheritance and consequences for the patient's body.
History of the disease and interesting historical facts
Peutz-Jeghers syndrome was first described in 1924 by German dermatologists August Peutz and Victor Jägers. They noted that the patient had signs of skin pigmentation and intestinal polyps. Since then, many studies have been conducted that have clarified the clinical and genetic features of this disease. Interestingly, the syndrome was only recognized in the second half of the 20th century, when genetic testing and molecular genetic studies became available, which created the possibility of a more detailed analysis of diseases associated with mutations in genes such as STK11/LKB1, which will lead to an understanding of the relevance of prevention.
Epidemiology
The epidemiology of Peutz-Jeghers syndrome is characterized by its rarity. According to current data, the incidence is about 1 person per 100,000 population. Since the disease is inherited in an autosomal dominant manner, it can occur in every family where there is a predisposition to this syndrome. However, the actual incidence of the disease may be underestimated due to the invisibility or underestimation of the polypous condition, which often leads to late diagnosis. In addition, it is necessary to take into account that this disease does not affect the gender, racial or ethnic predisposition of the population.
Genetic predisposition to this disease
Peutz-Jeghers syndrome is caused by mutations in the STK11 gene, located on chromosome 19. This gene encodes a protein that acts as a tumor suppressor, which determines its functions in regulating the cell cycle and metabolism. When the gene is mutated, this function is disrupted, leading to unlimited cell proliferation, which potentiates tumor development. Modern molecular genetic studies allow us to identify STK11 mutations in 60%-90% patients with the syndrome. However, there are cases with no mutations in this gene, which indicates the possibility of involvement of other genes, such as EIF4E, and the need for more attention to the individual characteristics of each case.
Risk factors for the development of this disease
The main risk factors for this condition, along with genetic predisposition, are various physical and chemical factors. In particular, the line of communication with the carcinogenic activity of tobacco and alcohol, environmental factors such as environmental pollution, as well as injuries and other mechanical effects that contribute to the occurrence of changes in tissues. Also, some infectious agents may be associated with an increased risk of developing tumor processes, but additional data indicate a greater likelihood of their occurrence not only due to the listed factors, but also as a result of combined effects that manifest themselves in late parental age and other circumstances.
Diagnosis of this disease
Diagnosis of Peutz-Jeghers syndrome is based on clinical examination, family history, and the presence of characteristic symptoms. The main symptoms include pigmentation of the skin and mucous membranes, as well as polyposis in the gastrointestinal tract. Laboratory studies may include tests for the presence of mutations in the STK11 gene. Radiological methods such as colonoscopy and gastroscopy are also used to visualize polyps. Other diagnostic methods, including participation in specialized genetic studies, play an important role in confirming the diagnosis. It is necessary to conduct a differential diagnosis with other hereditary diseases, such as Lynch syndrome and familial adenomatous polyposis.
Treatment
Treatment of Peutz-Jeghers syndrome is complex and may include both pharmacological therapy and surgical intervention. The main goal of treatment is to prevent complications associated with polyposis and the development of cancer. Pharmacological treatment includes the use of non-steroidal anti-inflammatory drugs to reduce the risk of polypous growth. Surgical treatment is indicated when large polyps or tumors are detected that require removal. In addition, monitoring of patients with regular monitoring of the condition and condition of polyps is also an important part of the overall treatment. This complex strategy allows for a more optimistic approach to the clearance of cancerous and precancerous lesions.
List of medications used to treat this disease
- Neasperin (aspirin) to reduce inflammation and polypous growth.
- Nonsteroidal anti-inflammatory drugs (NSAIDs) for regular monitoring.
- Immunotherapeutic agents (in case of malignant tumors) as an adjunct to surgical intervention.
- Chemotherapeutic drugs (if cancerous growths are detected).
- Other medications as prescribed by the doctor, taking into account the individual characteristics of the patient.
Disease monitoring
Patient monitoring includes regular medical check-ups, genetic testing for mutations, and routine examinations such as colonoscopy to detect polyps at an early stage. Prognosis depends on timely diagnosis and treatment, but patients with Peutz-Jeghers syndrome have an increased risk of developing cancer, which requires constant monitoring and observation. Complications may include malignant processes in various organs, especially in the intestine, which necessitates careful monitoring of the patient's condition.
Age-related features of the disease
Peutz-Jeghers syndrome can manifest itself at any age, but the first symptoms often appear in childhood or adolescence. Pigmentation and polyps can be detected during examinations in children, but the diagnosis may be established later. In adult age groups, there is a higher probability of developing malignant tumors, which requires attention to regular examinations. With age, the risk of occurrence and progression of the disease increases, which necessitates the adaptation of the monitoring and treatment plan to the age characteristics of the patient.
Questions and Answers
- What causes Peutz-Jeghers syndrome? Peutz-Jeghers syndrome is caused primarily by mutations in the STK11 gene, which is responsible for regulating cell growth and metabolism.
- How is Peutz-Jeghers syndrome diagnosed? Diagnosis of the syndrome involves clinical examination, genetic testing, and various imaging tests such as colonoscopy.
- What treatment is prescribed for Peutz-Jeghers syndrome? Treatment may include regular monitoring, drug therapy, and surgery to remove polyps and tumors.
- What is the risk of developing cancer in patients with Peutz-Jeghers syndrome? Patients with this syndrome have an increased risk of developing cancer, especially in the intestine, which requires close monitoring.
- What are the main symptoms of this syndrome? The main symptoms include pigmentation of the skin and mucous membranes, as well as the presence of polyps in the gastrointestinal tract.
